B群脑膜炎奈瑟菌的保护相关性及检测标准化——国际会议报告美国佐治亚州亚特兰大埃默里大学，2005年3月16 - 17日 - Suppr

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

作者信息

Borrow R, Carlone G M, Rosenstein N, Blake M, Feavers I, Martin D, Zollinger W, Robbins J, Aaberge I, Granoff D M, Miller E, Plikaytis B, van Alphen L, Poolman J, Rappuoli R, Danzig L, Hackell J, Danve B, Caulfield M, Lambert S, Stephens D

机构信息

Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom.

出版信息

Vaccine. 2006 Jun 12;24(24):5093-107. doi: 10.1016/j.vaccine.2006.03.091.

DOI:10.1016/j.vaccine.2006.03.091

PMID:16838413

Abstract

摘要

相似文献

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

Vaccine. 2006 Jun 12;24(24):5093-107. doi: 10.1016/j.vaccine.2006.03.091.

[Active immunization against serogroup B Neisseria meningitidis].

Enferm Infecc Microbiol Clin. 2003 Nov;21(9):513-9. doi: 10.1016/s0213-005x(03)72998-x.

Neisseria meningitidis serogroup B: laboratory correlates of protection.

FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):89-96. doi: 10.1111/j.1574-695X.2002.tb00608.x.

Comparison and correlation of neisseria meningitidis serogroup B immunologic assay results and human antibody responses following three doses of the Norwegian meningococcal outer membrane vesicle vaccine MenBvac.

Infect Immun. 2006 Aug;74(8):4557-65. doi: 10.1128/IAI.00466-06.

Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.

Vaccine. 2007 Mar 30;25(14):2537-8. doi: 10.1016/j.vaccine.2005.12.059. Epub 2006 Jan 20.

Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.

J Infect. 2017 Aug;75(2):81-94. doi: 10.1016/j.jinf.2017.05.001. Epub 2017 May 6.

Meningococcal B vaccine development and evaluation of efficacy.

Hum Vaccin. 2008 Mar-Apr;4(2):158-61. doi: 10.4161/hv.4.2.4871. Epub 2007 Aug 14.

An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.

Vaccine. 2011 Oct 13;29(44):7752-8. doi: 10.1016/j.vaccine.2011.07.124. Epub 2011 Aug 7.

Outer-membrane-vesicle vaccines: old but not forgotten.

Lancet Infect Dis. 2011 Jun;11(6):421-2. doi: 10.1016/S1473-3099(11)70096-2. Epub 2011 Apr 12.

Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro.

Clin Vaccine Immunol. 2009 Nov;16(11):1693-5. doi: 10.1128/CVI.00125-09. Epub 2009 Aug 26.

引用本文的文献

Interlaboratory study to assess precision and reproducibility of the meningococcal antigen surface expression (MEASURE) assay to quantify factor H binding protein expression at the surface of meningococcal serogroup B strains.

Diagn Microbiol Infect Dis. 2025 Oct;113(2):116920. doi: 10.1016/j.diagmicrobio.2025.116920. Epub 2025 May 30.

The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design.

Commun Biol. 2025 Jun 9;8(1):898. doi: 10.1038/s42003-025-08258-7.

Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccine.

mSphere. 2025 Apr 29;10(4):e0089824. doi: 10.1128/msphere.00898-24. Epub 2025 Apr 8.

A Bioluminescence-Based Serum Bactericidal Assay to Detect Bactericidal Antibodies Against in Human Sera.

Microorganisms. 2025 Mar 4;13(3):595. doi: 10.3390/microorganisms13030595.

Genomic characterization of invasive in Spain (2011/12-2022/23): expansion of clonal complex 213 and the potential threat to 4CMenB vaccine strain coverage.

Emerg Microbes Infect. 2025 Dec;14(1):2482696. doi: 10.1080/22221751.2025.2482696. Epub 2025 Mar 27.

Characterisation and Immunogenicity of outer membrane vesicles displaying NadA, NHBA and fHbp from serogroup B.

Front Immunol. 2024 Sep 24;15:1473064. doi: 10.3389/fimmu.2024.1473064. eCollection 2024.

Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.

NPJ Vaccines. 2024 Sep 1;9(1):159. doi: 10.1038/s41541-024-00953-6.

Current challenges and improvements in assessing the immunogenicity of bacterial vaccines.

Front Microbiol. 2024 Jul 9;15:1404637. doi: 10.3389/fmicb.2024.1404637. eCollection 2024.

Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 isolates causing invasive meningococcal disease in Argentina in 2010-2014.

Hum Vaccin Immunother. 2024 Dec 31;20(1):2378537. doi: 10.1080/21645515.2024.2378537. Epub 2024 Jul 22.

4CMenB journey to the 10-year anniversary and beyond.

Hum Vaccin Immunother. 2024 Dec 31;20(1):2357924. doi: 10.1080/21645515.2024.2357924. Epub 2024 Jul 8.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

作者信息

机构信息

Vaccine Evaluation Unit, Health Protection Agency, Manchester Royal Infirmary, Manchester M13 9WZ, United Kingdom.

出版信息

Vaccine. 2006 Jun 12;24(24):5093-107. doi: 10.1016/j.vaccine.2006.03.091.

DOI:10.1016/j.vaccine.2006.03.091

PMID:16838413

Abstract

摘要

相似文献

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

Vaccine. 2006 Jun 12;24(24):5093-107. doi: 10.1016/j.vaccine.2006.03.091.

[Active immunization against serogroup B Neisseria meningitidis].

Enferm Infecc Microbiol Clin. 2003 Nov;21(9):513-9. doi: 10.1016/s0213-005x(03)72998-x.

Neisseria meningitidis serogroup B: laboratory correlates of protection.

FEMS Immunol Med Microbiol. 2002 Oct 11;34(2):89-96. doi: 10.1111/j.1574-695X.2002.tb00608.x.

Infect Immun. 2006 Aug;74(8):4557-65. doi: 10.1128/IAI.00466-06.

Use of available outer membrane vesicle vaccines to control serogroup B meningococcal outbreaks.

Vaccine. 2007 Mar 30;25(14):2537-8. doi: 10.1016/j.vaccine.2005.12.059. Epub 2006 Jan 20.

Predicted vs observed effectiveness of outer membrane vesicle (OMV) vaccines against meningococcal serogroup B disease: Systematic review.

J Infect. 2017 Aug;75(2):81-94. doi: 10.1016/j.jinf.2017.05.001. Epub 2017 May 6.

Meningococcal B vaccine development and evaluation of efficacy.

Hum Vaccin. 2008 Mar-Apr;4(2):158-61. doi: 10.4161/hv.4.2.4871. Epub 2007 Aug 14.

An experimental outer membrane vesicle vaccine from N. meningitidis serogroup B strains that induces serum bactericidal activity to multiple serogroups.

Vaccine. 2011 Oct 13;29(44):7752-8. doi: 10.1016/j.vaccine.2011.07.124. Epub 2011 Aug 7.

Outer-membrane-vesicle vaccines: old but not forgotten.

Lancet Infect Dis. 2011 Jun;11(6):421-2. doi: 10.1016/S1473-3099(11)70096-2. Epub 2011 Apr 12.

Investigation on the effect of immune selection on resistance to bactericidal antibodies to group B meningococci in vitro.

Clin Vaccine Immunol. 2009 Nov;16(11):1693-5. doi: 10.1128/CVI.00125-09. Epub 2009 Aug 26.

引用本文的文献

Diagn Microbiol Infect Dis. 2025 Oct;113(2):116920. doi: 10.1016/j.diagmicrobio.2025.116920. Epub 2025 May 30.

The characterization of Klebsiella pneumoniae associated with neonatal sepsis in low- and middle-income countries to inform vaccine design.

Commun Biol. 2025 Jun 9;8(1):898. doi: 10.1038/s42003-025-08258-7.

Methods to evaluate the performance of a multicomponent meningococcal serogroup B vaccine.

mSphere. 2025 Apr 29;10(4):e0089824. doi: 10.1128/msphere.00898-24. Epub 2025 Apr 8.

A Bioluminescence-Based Serum Bactericidal Assay to Detect Bactericidal Antibodies Against in Human Sera.

Microorganisms. 2025 Mar 4;13(3):595. doi: 10.3390/microorganisms13030595.

Genomic characterization of invasive in Spain (2011/12-2022/23): expansion of clonal complex 213 and the potential threat to 4CMenB vaccine strain coverage.

Emerg Microbes Infect. 2025 Dec;14(1):2482696. doi: 10.1080/22221751.2025.2482696. Epub 2025 Mar 27.

Characterisation and Immunogenicity of outer membrane vesicles displaying NadA, NHBA and fHbp from serogroup B.

Front Immunol. 2024 Sep 24;15:1473064. doi: 10.3389/fimmu.2024.1473064. eCollection 2024.

Type 5 secretion system antigens as vaccines against Gram-negative bacterial infections.

NPJ Vaccines. 2024 Sep 1;9(1):159. doi: 10.1038/s41541-024-00953-6.

Current challenges and improvements in assessing the immunogenicity of bacterial vaccines.

Front Microbiol. 2024 Jul 9;15:1404637. doi: 10.3389/fmicb.2024.1404637. eCollection 2024.

Genetic characterization and estimated 4CMenB vaccine strain coverage of 284 isolates causing invasive meningococcal disease in Argentina in 2010-2014.

Hum Vaccin Immunother. 2024 Dec 31;20(1):2378537. doi: 10.1080/21645515.2024.2378537. Epub 2024 Jul 22.

4CMenB journey to the 10-year anniversary and beyond.

Hum Vaccin Immunother. 2024 Dec 31;20(1):2357924. doi: 10.1080/21645515.2024.2357924. Epub 2024 Jul 8.

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

作者信息

机构信息

出版信息

相似文献

引用本文的文献

文献AI研究员

用中文搜PubMed

文档翻译

Suppr 超能文献

Neisseria meningitidis group B correlates of protection and assay standardization--international meeting report Emory University, Atlanta, Georgia, United States, 16-17 March 2005.

作者信息

机构信息

出版信息

相似文献

引用本文的文献